India's 10th Indian Pharmacopoeia Edition Sets New Standards for Global Healthcare
Image Source: Internet
Union Health Minister J P Nadda has unveiled the 10th edition of the Indian Pharmacopoeia, a landmark publication that sets the gold standard for India's pharmaceutical industry. This comprehensive guide to drug standards has gained international recognition, with its standards now accepted in 19 countries of the Global South. The Indian Pharmacopoeia 2026 boasts 121 new monographs, bringing the total to 3,340, and significantly strengthens coverage across key therapeutic categories, including medicines for tuberculosis, diabetes, cancer, and iron supplements. This ensures more comprehensive standardization of medications used in national health programs. The Indian government's commitment to healthcare diplomacy has led to international acceptance of the country's pharmacopoeia standards. The Pharmacovigilance Programme of India (PvPI) has made remarkable progress, with India rising from 123rd globally in 2009-2014 to 8th position in 2025 in terms of contributions to the World Health Organization's pharmacovigilance database. The inclusion of 20 blood component monographs in the Indian Pharmacopoeia 2026 marks a significant milestone in transfusion medicine, aligning with the Drugs and Cosmetics Rules of 2020. This edition reflects the government's sustained effort towards quality, transparency, and public welfare, making India a leader in pharmaceutical manufacturing and regulation.
